Collegium Pharmaceutical announced Thursday a $50 million accelerated share repurchase through Jefferies, delivered in pre-market and met with immediate buying. The ADHD-focused drugmaker receives roughly 80% of the shares immediately, with final settlement tied to volume-weighted average price over the execution window. No maturity disclosed, but ASRs of this size typically close in 60 to 90 days.
The structure is clean and orthodox. Collegium pays the full $50 million upfront. Jefferies borrows shares, delivers them to the company for immediate retirement, then works the hedge in the open market without disrupting the tape. The company locks in buyback size today and eliminates execution risk. The trade-off: Collegium surrenders any upside from patient open-market timing and pays the embedded financing cost in the price adjustment.
Collegium's flagship product is Jornay PM, an evening-dosed methylphenidate for ADHD that competes in a category seeing sustained script growth but tightening reimbursement. The ASR arrives as the company navigates patent cliffs and generic encroachment across its older assets. Pricing in ADHD has held—commercial plans have not yet moved to aggressive step edits—but utilization management is tightening in Medicare Advantage and state Medicaid. Collegium's decision to retire $50 million in equity now, rather than preserve dry powder or accelerate pipeline investment, suggests management sees limited near-term deployment opportunities with better risk-adjusted returns than buybacks at current valuation.
This is Collegium's second meaningful capital return in 18 months. The board authorized a $100 million buyback program in late 2023, and this ASR likely exhausts half that authorization in a single trade. The velocity matters. When specialty pharma moves to ASR instead of dribbling buybacks over quarters, it signals one of two postures: materially undervalued equity or a thin pipeline that cannot absorb incremental R&D capital efficiently. Collegium's enterprise value sits near $800 million, so this represents over 6% of market cap retired in one print.
Allocators should track Jornay PM formulary status on 2025 Medicare Advantage plans, published in October. If the product holds preferred status without prior authorization, the ASR reads as offense. If it drops a tier or gains step therapy, this buyback becomes defense—returning cash before the margin compression arrives. Jefferies will be working the hedge through mid-Q2, so any unusual volume or price action in that window reflects mechanical flow, not fresh fundamental news.
Collegium reports Q1 earnings in early May. The ASR will reduce the share count, lifting EPS optically, but the $50 million outflow also depletes balance sheet flexibility for in-licensing or late-stage asset acquisition—the typical growth path for single-product specialty pharma. The Jefferies execution starts now.